Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 58 for “"Residual disease"”.
-
Molecular Determinants of Residual Disease In Ovarian Cancer
… surgery followed by adjuvant chemotherapy. Residual disease followed by surgery is associated with adverse overall and progression-free survival as well as poor response to adjuvant chemotherapy. Accurate identification of patients at high risk of residual disease will help avoid unnecessary …
-
Multi-Modality Plasma-Based Detection of Minimal Residual Disease in Triple-Negative Breast Cancer
… of tumor in patients who are technically “disease-free” after neoadjuvant chemotherapy and surgery as early as possible might be able to predict recurrence of patients, and then provide timely intervention for additional therapy. To this end, I applied the analysis of “liquid biopsies” for …
-
Electrorotation and Dielectric Profiling: Advanced Strategies for Detecting Minimal Residual Disease in Multiple Myeloma
Il mieloma multiplo (MM) è una neoplasia ematologica incurabile caratterizzata dall'espansione clonale delle plasmacellule tumorali che producono anticorpi monoclonali non funzionali. È caratterizzato da una marcata eterogeneità genetica e clinica che complicano il trattamento e determinano …
-
Impact of no residual versus residual disease after hysterectomy for stage 1 cervical cancer on recurrence
… cancer following hysterectomy for stage I disease are well established. The impact of residual disease after LEEP in patients undergoing hysterectomy for stage 1 cervical cancer on recurrence has not been extensively studied. Design and Methods: Records of all patients who underwent …
-
Clinical Impact of A Highly Sensitive Next-Generation Sequencing Measurable Residual Disease Assay In Patients With Acute Lymphoblastic Leukemia
<p>Measurable residual disease (MRD) is highly prognostic for relapse and overall survival (OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent “MRD negativity” by standard assays still relapse. We evaluated the clinical impact of a highly sensitive next-generation …
-
The significance of aberrant phenotypes and multidrug resistance for evaluation of the dynamics of minimal residual disease in acute leukemia patients /
… the original flow cytometric assay for minimal residual disease detection. We found that several aberrant phenotypes of patients with acute myelogenous leukemia (CD13+CD33+CD56+, CD5+, CD7+) are related to an increased multidrug resistance and through this mechanism influence a higher level of …
-
Sergančiųjų ūmine leukemija aberantinių fenotipų ir dauginio atsparumo vaistams nustatymas ir svarba vertinant minimalios liekamosios ligos dinamiką /
… patients and assess their impact on minimal residual disease dynamics. 114 patients with newly diagnosed acute leukemia were included in the study. 35 patients had acute B-lymphoblastic leukemia, 29 - acute T-lymphoblastic leukemia, 50 - acute myelogenous leukemia. The control group consisted …
-
An in vivo RNAi therapy screen identifies novel mediators of leukemia-microenvironment interaction
Minimal residual disease refers to those cancer cells that persist following initial therapy. In precursor B-cell acute lymphoblastic leukemia (BCP-ALL), the presence of minimal residual disease is a strong prognostic indicator of relapse. The establishment of minimal residual disease fundamentally …
-
Combining mechanistic modelling with data-driven modelling in mathematical oncology
… relapse problem. We investigate the dynamics of residual disease in individual patients to mathematically model leukemia evolution in observed response and relapse kinetics. We developed stochastic and deterministic, patient-specific models that can integrate longitudinal measurable residual …
-
THE USE OF THE CONE-BEAM COMPUTED TOMOGRAPHY FUSION IMAGING AND OF DEDICATED SOFTWARE FOR ABLATION VOLUME PREDICTION IN PERCUTANEOUS MICROWAVE ABLATION OF LIVER PRIMARY TUMORS
… and 6 months were reviewed to assess outcomes as residual disease, local tumor progression, intrahepatic distant recurrence, local and overall disease survival rates. Follow-up at 1, 3 and 6 months in group A and B was available in 100%, 57%, 38% and in 100%, 49% and 35% of cases respectively. …
-
Evaluation of novel prognostic factors In ovarian carcinoma
… markers of survival and RFS were FIGO stage, and residual disease in 173 and 178 patients respectively. Data on CA 125 serum level, (available in 89 patients) was a marker of prognostic significance in the patients treated with platinum based chemotherapy. CA 125 and CEA antigen expression were …
-
A Review of Women with Epithelial Ovarian Carcinoma in a Middle-Income setting: Groote Schuur Hospital, Cape Town, South Africa: Demographics, Treatment and Outcomes of Patients between 2005 and 2015
… to manage with a poor prognosis for latestage disease and high recurrence rates. Ovarian Carcinoma ranks 8th amongst new cancer cases in women and accounts for 4.7% of reported cancer deaths.1 Women often present late with advanced disease of which the prognosis remains poor. The 5-year …
-
An audit of the management of women with Borderline Ovarian Tumours treated at Groote Schuur Hospital between 1984-2008
… of the women were alive with no evidence of disease. Univariate analysis, indicated that the histological subtype of tumour, the type of surgery, the presence of residual disease, advanced stage disease, the presence of ascites were all statistically significant in affecting survival. …
-
Improving the Monitoring of Multiple Myeloma Patients Using Blood Based Markers of Disease
… the M-protein. Multiple myeloma is a complex disease, and despite great advances in both detection and treatment of the disease, there remains a vast amount of interest in improving patient outcomes. In the era of novel agents and clinical trials, patients with MM are living longer and there …
-
Improving Quantitative Treatment Response Monitoring With Deformable Image Registration
… (P<0.05). The positive predictive power for residual disease was 63% compared to 50% for contrast enhanced post-RT CT. Specific aim 2 was designed to use parotid gland standardized uptake value (SUV) as an objective imaging biomarker for salivary toxicity. We found that relative change in …
-
BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
… to nearly 90%. However, the problems of minimal residual disease and relapsed and refractory disease persist. Personalized, targeted therapies have improved outcomes among the minority of patients for whom chemotherapy is ineffective. Immunotherapy, specifically bispecific T-cell engaging …
-
The clonal architecture and tumour microenvironment of breast cancers are shaped by neoadjuvant chemotherapy
… linearly correlating with the degree of residual disease remaining after chemotherapy. Finally, the circulating tumour DNA (ctDNA) genomic landscape was explored by using shallow whole genome sequencing and targeted sequencing of plasma DNA. Tumour mutations detected on exome sequencing …
-
Characterisation of the mechanisms of tumour-induced dysfunction of clonal T cell expansions in multiple myeloma
… in therapy, relapse is inevitable due to residual disease and myeloma remains incurable. New therapies are required to remove residual disease and maintain long term survival. Expanded clones of cytotoxic T cells have been detected in myeloma and their presence is associated with improved …
Page 1 of 3